ClinicalTrials.gg
TerminatedNCT00089115Updated Aug 2, 2013

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

A Phase 3 interventional study of autologous immunoglobulin idiotype-KLH conjugate vaccine and rituximab in Lymphoma, sponsored by Favrille. Terminated at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-02.

Sponsored by Favrille · Phase 3, Interventional, and Treatment

Why this study was terminated
Withdrawn as company has shut down and filed for bankruptcy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.

Started
2004
with 26 others
Phase 3
26 of 253
1 open now
Registered
69th of 253
by date

Among the 253 studies testing rituximab in Lymphoma, this one is one of 27 that started in 2004, is one of 26 in phase 3, and was the 69th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies testing rituximab in Lymphoma, or all of them as a file.
02

Study summary

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow and peripheral blood. It is not yet known whether combining rituximab and GM-CSF with vaccine therapy may cause a stronger immune response and kill more cancer cells.

PURPOSE: This randomized phase III trial is studying giving rituximab and GM-CSF together with vaccine therapy and comparing it to giving rituximab and GM-CSF alone in treating patients with newly diagnosed, relapsed, or refractory B-cell non-Hodgkin's lymphoma.

Read the detailed description

OBJECTIVES:

Primary

  • Compare time to disease progression in patients with grade 1, 2, or 3 follicular B-cell non-Hodgkin's lymphoma who respond (i.e., complete or partial response, or stable disease) to treatment with rituximab and are then treated with sargramostim (GM-CSF) with vs without autologous immunoglobulin idiotype-KLH conjugate vaccine.

Secondary

  • Compare response rate improvement in patients treated with these regimens.
  • Compare overall complete response rate in patients treated with these regimens.
  • Compare duration of response in patients treated with these regimens.
  • Determine the safety of these regimens in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to prior treatment (yes vs no) and response to rituximab during study (complete response [CR] or partial response [PR] vs stable disease [SD]).

All patients receive rituximab IV once weekly for 4 weeks. Five weeks after the last dose of rituximab, patients are assessed for response. Patients with progressive disease are removed from the study and do not undergo randomization. Patients with a CR, PR, or SD are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine subcutaneously (SC) on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4.
  • Arm II: Patients receive placebo SC on day 1. Patients also receive GM-CSF SC on days 1-4.

In both arms, treatment repeats monthly for 6 months in the absence of unacceptable toxicity or clinically significant progressive disease. After the first 6 months, patients with a CR, PR, or SD may continue to receive treatment (per treatment arm as above) every 2 months for 1 year (total of 6 doses) and then every 3 months thereafter in the absence of disease progression.

Patients are followed every 3 months for 2 years and then every 6 months until disease progression.

PROJECTED ACCRUAL: A total of 342 evaluable patients (171 per treatment arm) will be accrued for this study within 18 months.

03

Conditions studied

  • Lymphoma

Keywords

  • contiguous stage II grade 1 follicular lymphoma
  • contiguous stage II grade 2 follicular lymphoma
  • contiguous stage II grade 3 follicular lymphoma
  • noncontiguous stage II grade 1 follicular lymphoma
  • noncontiguous stage II grade 2 follicular lymphoma
  • noncontiguous stage II grade 3 follicular lymphoma
  • stage I grade 1 follicular lymphoma
  • stage I grade 2 follicular lymphoma
  • stage I grade 3 follicular lymphoma
  • stage III grade 1 follicular lymphoma
  • stage III grade 2 follicular lymphoma
  • stage III grade 3 follicular lymphoma
  • stage IV grade 1 follicular lymphoma
  • stage IV grade 2 follicular lymphoma
  • stage IV grade 3 follicular lymphoma
  • recurrent grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • recurrent grade 3 follicular lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed follicular B-cell non-Hodgkin's lymphoma (NHL)

    • Grade 1, 2, or 3
  • Meets 1 of the following criteria for treatment with rituximab:

    • Treatment naïve
    • disease after prior chemotherapy
    • Relapsed after a prior documented response (i.e., complete or partial response) to rituximab of at least 6 months duration
  • Tumor accessible for OR existing biopsy material (taken within the past 6 months) suitable for vaccine preparation
  • Measurable or evaluable disease after tumor tissue procurement for vaccine production
  • No more than 2 prior treatment regimens for NHL

    • Single regimens include any of the following:

      • Maintenance rituximab
      • Rituximab administered once weekly for 8 courses
      • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab* NOTE: *CHOP followed by rituximab at time of relapse is considered 2 treatment regimens
  • No history of CNS lymphoma or meningeal lymphomatosis

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • 0-1

  • Not specified

Hematopoietic

  • Absolute granulocyte count ≥ 1,500/mm\^3
  • count ≥ 75,000/mm\^3 (unless related to bone marrow involvement by lymphoma)
  • ≥ 10g/dL

Hepatic

  • Not specified

Renal

  • Not specified

Cardiovascular

  • No congestive heart failure

Pulmonary

  • No compromised pulmonary function

Immunologic

  • negative
  • No prior allergic response to GM-CSF
  • No active bacterial, viral, or fungal infection

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No psychiatric disorder that would preclude study participation
  • No other within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No other serious nonmalignant disease that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • See Chemotherapy
  • At least 4 weeks since prior immunotherapy
  • No prior radiolabeled anti-lymphoma antibody (e.g., iodine I 131 tositumomab or ibritumomab tiuxetan)
  • No prior or allogeneic stem cell transplantation
  • No prior lymphoma-specific idiotype immunotherapy (e.g., Id vaccine)
  • No prior vaccine or immunotherapeutic containing keyhole limpet hemocyanin (KLH)

Chemotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • More than 9 months since prior fludarabine
  • More than 2 years since prior chemotherapy/rituximab combination therapy (e.g., CHOP/rituximab or cyclophosphamide, vincristine, and prednisone [CVP]/rituximab)
  • No more than 6 total prior treatment courses with fludarabine

Endocrine therapy

  • No concurrent for allergic reaction to sargramostim (GM-CSF)

Radiotherapy

  • See Biologic therapy
  • At least 4 weeks since prior radiotherapy

Surgery

  • Not specified

Other

  • At least 4 weeks since prior experimental therapy
  • No concurrent systemic therapy
  • No other concurrent anti-lymphoma therapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
Double

Interventions

  • Biologicalautologous immunoglobulin idiotype-KLH conjugate vaccine
  • Biologicalrituximab
  • Biologicalsargramostim
06

What researchers measure

Primary outcomes

  1. Time to progression after 248 patients have progressed

Secondary outcomes

  1. Response rate improvement after 248 patients have progressed

  2. Overall complete response rate by modified Cheson Criteria after 248 patients have progressed

  3. Duration of response by modified Cheson Criteria after 248 patients have progressed

  4. Safety by Common Toxicity Criteria (CTC) after 248 patients have progressed

07

Study locations

60 sites
  • Comprehensive Cancer Center at University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • Rebecca and John Moores UCSD Cancer Center
    La Jolla, California 92093-0658, United States
  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • USC/Norris Comprehensive Cancer Center and Hospital
    Los Angeles, California 90089, United States
  • Hoag Cancer Center at Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego
    San Diego, California 92120, United States
  • Sharp Memorial Hospital Cancer Center
    San Diego, California 92123, United States
  • UCSF Comprehensive Cancer Center
    San Francisco, California 94143-0324, United States
  • Stanford Cancer Center at Stanford University Medical Center
    Stanford, California 94305, United States
  • Kaiser Permanente Medical Center - Vallejo
    Vallejo, California 94589, United States
  • Rocky Mountain Cancer Centers - Denver Midtown
    Denver, Colorado 80218, United States
  • Medical Oncology Hematology Consultants, P.A. at Helen F. Graham Cancer Center
    Newark, Delaware 19713-2055, United States
  • Lombardi Cancer Center at Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Center for Hematology-Oncology - Boca Raton
    Boca Raton, Florida 33486, United States
  • University of Florida Health Science Center - Jacksonville
    Jacksonville, Florida 32209, United States
  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
    Tampa, Florida 33612-9497, United States
  • North Idaho Cancer Center
    Coeur d'Alene, Idaho 83814, United States
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202, United States
  • Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    Kansas City, Kansas 66160-7357, United States
  • Markey Cancer Center at University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536-0084, United States
  • Ochsner Cancer Institute at Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204-6881, United States
  • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201-1379, United States
  • Josephine Ford Cancer Center at Henry Ford Hospital
    Detroit, Michigan 48202-2608, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Siteman Cancer Center at Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Montana Cancer Specialists at Montana Cancer Center
    Missoula, Montana 59802, United States
  • New Mexico Cancer Center
    Albuquerque, New Mexico 87109, United States
  • Our Lady of Mercy Medical Center Comprehensive Cancer Center
    Bronx, New York 10466-2604, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Beth Israel Medical Center - Philipps Ambulatory Care Center
    New York, New York 10003, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Comprehensive Cancer Center at Wake Forest University
    Winston-Salem, North Carolina 27157-1082, United States
  • Mid Dakota Clinic, P. C.
    Bismarck, North Dakota 58502-5538, United States
  • Roger Maris Cancer Center at MeritCare Hospital
    Fargo, North Dakota 58122, United States
  • Charles M. Barrett Cancer Center at University Hospital
    Cincinnati, Ohio 45219, United States
  • Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
    Cleveland, Ohio 44106-5047, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
    Columbus, Ohio 43210-1240, United States
  • Providence Cancer Center at Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Kaiser Permanente Medical Office - Interstate Medical Office Central
    Portland, Oregon 97227, United States
  • Cancer Institute at Oregon Health and Science University
    Portland, Oregon 97239-3098, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822-0001, United States
  • Fox Chase-Temple Cancer Center
    Philadelphia, Pennsylvania 19111-2497, United States
  • Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Sarah Cannon Cancer Center at Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • Baylor University Medical Center - Dallas
    Dallas, Texas 75246, United States
  • M.D. Anderson Cancer Center at University of Texas
    Houston, Texas 77030-4009, United States
  • Cancer Care Network of South Texas
    San Antonio, Texas 78229, United States
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22908, United States
  • Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
    Seattle, Washington 98104, United States
  • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
    Yakima, Washington 98902, United States
  • University of Wisconsin Comprehensive Cancer Center
    Madison, Wisconsin 53792-6164, United States
  • Marshfield Clinic - Marshfield Center
    Marshfield, Wisconsin 54449, United States
08

References and documents

Publications

  • Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009 Jun 20;27(18):3036-43. doi: 10.1200/JCO.2008.19.8903. Epub 2009 May 4. PubMed 19414675 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00089115
Lead sponsor
Favrille
First posted
Aug 5, 2004
Start date
Jul 2004
Last update
Aug 2, 2013

Study contacts

John F. Bender, PharmD
study chair · Favrille
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Sargramostim

Start the discussion